Table 3.
Frequency of discussion and/or documentation of fertility-preserving options and fetotoxicity of commonly prescribed renal drugs (% of providers)
| How often do you document each of the following items for your adolescent patients? | Never | Rarely | Sometimes | Often | Always |
|---|---|---|---|---|---|
| Documentation of a discussion on the risk of fetotoxicity with ACEis/ARBs or mycophenolate use | 0.0 | 0.0 | 6.9 | 16.7 | 76.3 |
| Document a negative pregnancy test before starting a fetotoxic medication | 9.9 | 27.0 | 16.9 | 18.3 | 28.2 |
| Discuss the risk of infertility with cyclophosphamide | 0 | 0 | 1.5 | 5.9 | 92.6 |
| Discuss the fertility-preserving options (hormonal ovarian suppression and oocyte cryopreservation) with exposure to cyclophosphamide | 4.5 | 7.6 | 13.6 | 28.8 | 45.5 |
| Discussion on patient’s desire for future pregnancy | 1.4 | 20.0 | 37.1 | 27.1 | 14.2 |
ACEis, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers.